| Risk | Moderately High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.68% |
| NAV | ₹10.14 (30 Oct 2020) |
|---|---|
| Fund Started | 29 Dec 2019 |
| Fund Size | ₹230 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Reliance Industries Ltd. | Energy | Equity | 4.2% |
| Infosys Ltd. | Technology | Equity | 4.0% |
| HDFC Bank Ltd. | Financial | Equity | 3.5% |
| ICICI Bank Ltd. | Financial | Equity | 3.5% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 2.8% |
| Tata Consultancy Services Ltd. | Technology | Equity | 2.7% |
| Hindustan Unilever Ltd. | FMCG | Equity | 2.7% |
| Atul Ltd. | Chemicals | Equity | 2.7% |
| Bayer CropScience Ltd. | Healthcare | Equity | 2.6% |
| Strides Pharma Science Ltd. | Healthcare | Equity | 2.5% |
Mahindra Manulife Top 250 Nivesh Yojana Direct Growth is a Equity Mutual Fund Scheme launched by Mahindra Mutual Fund. This scheme was made available to investors on 29 Dec 2019. V Balasubramanian is the Current Fund Manager of Mahindra Manulife Top 250 Nivesh Yojana Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹230 Cr and the Latest NAV as of 30 Oct 2020 is ₹10.14.
The Mahindra Manulife Top 250 Nivesh Yojana Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 1000. Exit load of 1%, if redeemed within 1 year.
The Scheme seeks long term capital growth through investments in equity and equity related securities of both large cap and mid cap stocks.